Joel Schneider Net Worth

The estimated Net Worth of Joel Solomon Zev Schneider is at least $2.69 Milion dollars as of 14 March 2022. Joel Schneider owns over 30,504 units of Solid Biosciences Inc stock worth over $1,769,662 and over the last 7 years he sold SLDB stock worth over $918,564. In addition, he makes $0 as Chief Technology Officer and Head of Exploratory Research and Development at Solid Biosciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Joel Schneider SLDB stock SEC Form 4 insiders trading

Joel has made over 5 trades of the Solid Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 30,504 units of SLDB stock worth $33,554 on 14 March 2022.

The largest trade he's ever made was selling 30,504 units of Solid Biosciences Inc stock on 14 March 2022 worth over $33,554. On average, Joel trades about 7,607 units every 93 days since 2018. As of 14 March 2022 he still owns at least 236,270 units of Solid Biosciences Inc stock.

You can see the complete history of Joel Schneider stock trades at the bottom of the page.

Joel Schneider biography

Dr. Joel Schneider Ph.D. serves as Chief Technology Officer and Head of Exploratory Research and Development of the Company. He also served as an Analyst from March 2014 to March 2015, a Director from March 2015 to January 2017 and our Vice President of Research and Development from January 2017 to June 2017. Prior to joining us, Dr. Schneider completed a postdoctoral fellowship at Harvard University in the Department of Stem Cell and Regenerative Biology from January 2013 to 2014. He holds a Ph.D. in Cell Biology and Molecular Medicine from Rutgers University and a B.A. in Biology from Brandeis University.

How old is Joel Schneider?

Joel Schneider is 35, he's been the Chief Technology Officer and Head of Exploratory Research and Development of Solid Biosciences Inc since 2017. There are 22 older and no younger executives at Solid Biosciences Inc. The oldest executive at Solid Biosciences Inc is Stephen J. DiPalma M.B.A., 62, who is the Treasurer & Principal Accounting Officer.

What's Joel Schneider's mailing address?

Joel's mailing address filed with the SEC is 5th, 141 Portland St, Cambridge, MA 02139, USA.

Insiders trading at Solid Biosciences Inc

Over the last 7 years, insiders at Solid Biosciences Inc have traded over $9,620,465 worth of Solid Biosciences Inc stock and bought 13,973,934 units worth $97,227,521 . The most active insiders traders include Advisors Llcperceptive Life..., Capital Management, L.P.Ra ... a Rajeev M. Shah. On average, Solid Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $1,822,871. The most recent stock trade was executed by Ian F Smith on 3 July 2024, trading 3,255 units of SLDB stock currently worth $24,380.

What does Solid Biosciences Inc do?

solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.

Complete history of Joel Schneider stock trades at Solid Biosciences Inc

Solid Biosciences Inc executives and stock owners

Solid Biosciences Inc executives and other stock owners filed with the SEC include:

• Carl Morris,
  Chief Scientific Officer
• Ilan Ganot,
  President, Chief Executive Officer, Co-Founder, Director
• Jennifer Ziolkowski,
  Chief Financial Officer, Treasurer
• Ilan Ganot,
  Co-founder, Pres, CEO & Director
• Dr. Carl Ashley Morris,
  Chief Scientific Officer
• Adam Koppel,
  Independent Director
• Lynne Sullivan,
  Independent Director
• Martin Freed,
  Independent Director
• Dr. Andrey Juan Zarur Ph.D.,
  Co-Founder
• Adam Stone,
  Independent Director
• Sukumar Nagendran,
  Independent Director
• Matthew Arnold,
  Independent Director
• Rajeev Shah,
  Independent Director
• Robert Huffines,
  Independent Director
• Ian F. Smith A.C.A., ACA, C.P.A., CPA,
  Exec. Chair
• Matthew Bennett Arnold,
  Co-Founder & Board Member
• Carlo Tanzi,
  IR Contact Officer
• Lynette Herscha,
  Chief Legal Officer and Secretary
• Joel Schneider,
  Chief Technology Officer and Head of Exploratory Research and Development
• Ian Smith,
  Chairman of the Board
• Gilad David Hayeem,
  Co-Founder
• Dr. Cathryn M. Clary M.B.A., M.D.,
  Acting Chief Medical Officer
• Erin Powers Brennan,
  Chief Legal Officer & Sec.
• Caitlin Lowie,
  VP of Communications & IR
• Stephen J. DiPalma M.B.A.,
  Treasurer & Principal Accounting Officer
• Dr. Joel Solomon Zev Schneider Ph.D.,
  Chief Operating Officer
• Michael Inbar CPA, M.B.A.,
  Sr. VP of Fin.
• Annie Ganot,
  Co-Founder & Director of Patient Advocacy
• Pedro Alvaro Amorrortu,
  Chief Operating Officer
• Jorge Armando Quiroz,
  Chief Medical Officer
• Capital Management, L.P.Ra ...,
  
• Advisors Llcperceptive Life...,
  
• Chase & Cojpmc Strategic In...,
  
• Advisors Llcedelman Joseph ...,
  
• Gilad David Hayeem,
  10% owner
• Juan Andrey Zarur,
  Director
• Kevin Tan,
  CFO & Treasurer
• Capital, Llc Boxer,
  10% owner
• Capital Management, L.P.Ra ...,
  
• Capital Life Sciences Inves...,
  
• Advisors Llcperceptive Life...,
  
• Capital Management, L.P.Ra ...,
  
• Jessie Hanrahan,
  Chief Regulatory Officer
• Erin Powers Brennan,
  Chief Legal Officer, Secretary
• Clare Kahn,
  
• Advisors Llcperceptive Life...,
  
• David T Howton,
  Chief Operating Officer
• Jennifer Marlowe,
  CSO
• Alexander Cumbo,
  President and CEO
• Paul Herzich,
  Chief Technology Officer
• Gabriel Brooks,
  Chief Medical Officer
• Georgia Keresty,